ClinicalTrials.gg

Program

SAR447971

A development code.

In Sanofi's pipeline, IRAK4 degrader. Its studies are mostly in Hidradenitis, led by Sanofi.

Furthest: phase 1, since May 22, 20261 company-led study, 1 open or runningNext primary completion: Apr 17, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 1since May 22, 2026May 22, 2026Apr 17, 2028phase 1 · NCT07629336
  • Named in Sanofi’s own pipeline as SAR447971, phase 1, as of Sep 30, 2026 (source).

Also a collaborator on its studies: kymera-therapeutics-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 22, 2026First study: phase 1 study in HidradenitisFirst studyNCT07629336 · 122 planned · Netherlands

Ahead

  1. Apr 17, 2028Primary completion: phase 1 study in HidradenitisNCT07629336

TargetBeta

“IRAK4 degrader”the company's pipeline, read by Claude · source

Other programs on IRAK4

ProgramCompanyFurthest phaseStudies
emavusertibrulecuris-incphase 23
IRAK4 Inhibitor AZD2962ruleAstraZenecaphase 11
ARD-885ruleartivila-shenzhen-innovation-center-ltdphase 11
HPB-092rulehangzhou-polymed-biopharmaceuticals-incphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07629336Hidradenitis · Netherlands1RecruitingApr 17, 2028122

How it is read

Names in the registry

  • “SAR447971”, 1 entry

Codes read as this program: SAR447971.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.